Live Analyst Rating Changes 23245 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sam Slutsky
LIFE

Sam Slutsky

Wall Street Analyst
★★★★☆
#638
on 13Foresight · ranked by our own returns
55%
Success Rate
+9.3%
Average Return
35 of 64 calls profitable · +7.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 55% of Sam Slutsky's ratings turned a profit when each position was held for 1 year — averaging +9.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

239 Buy 17 Hold 0 Sell
Sam's Stock Coverage 22 ratings · 2026-08-12
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
OLMA
Olema Pharmaceuticals
Aug 11, 2026 BUY Strong Buy
+252.5% avg upside
16 analysts
$24.00
130.14% Upside
+0.0% ·
DMRA
Damora Therapeutics
Aug 11, 2026 BUY Strong Buy
-4.7% avg upside
20 analysts
$45.00
48.12% Upside
· ·
SYRE
Spyre Therapeutics
Aug 11, 2026 BUY Strong Buy
-8.7% avg upside
23 analysts
$129.00
25.50% Upside
· ·
ORKA
Oruka Therapeutics
Aug 11, 2026 BUY Strong Buy
+20.5% avg upside
16 analysts
$175.00
67.13% Upside
+0.0% ·
COGT
Cogent Biosciences
Aug 10, 2026 BUY Strong Buy
-4.4% avg upside
26 analysts
$55.00
42.09% Upside
-6.7% ·
ELVN
Enliven Therapeutics
Aug 08, 2026 BUY Strong Buy
-1.9% avg upside
14 analysts
$70.00
19.15% Upside
+0.0% ·
IMVT
Immunovant
Aug 07, 2026 BUY Strong Buy
-1.8% avg upside
24 analysts
$53.00
29.43% Upside
+6.6% ·
CGON
CG Oncology, Inc.
Aug 07, 2026 BUY Strong Buy
+11.8% avg upside
17 analysts
$108.00
40.29% Upside
+2.6% ·
CLDX
Celldex
Aug 07, 2026 BUY Strong Buy
-6.9% avg upside
28 analysts
$56.00
26.23% Upside
-0.0% ·
IFRX
InflaRx
Aug 06, 2026 BUY Buy
+348.8% avg upside
11 analysts
$5.00
150.02% Upside
+7.0% ·
ALXO
ALX Oncology Holdings
Aug 06, 2026 HOLD Strong Buy
+829.7% avg upside
11 analysts
-6.2% ·
OKUR
OnKure Therapeutics
Aug 05, 2026 BUY Buy
+480.9% avg upside
13 analysts
$16.00
291.11% Upside
-0.5% ·
PVLA
Palvella Therapeutics
Aug 05, 2026 BUY Strong Buy
+9.4% avg upside
27 analysts
$236.00
52.98% Upside
-0.4% ·
TSE:EPRX
Eupraxia Pharmaceuticals
Jul 31, 2026 BUY Strong Buy
+138.7% avg upside
9 analysts
$22.32
138.82% Upside
+5.3% ·
QNCX
Quince Therapeutics
Jul 30, 2026 BUY Buy
+564.2% avg upside
16 analysts
$99.00
202.51% Upside
+31.1% ·
TCRX
TScan Therapeutics
Jul 29, 2026 BUY Strong Buy
+995.3% avg upside
12 analysts
$6.00
672.42% Upside
+2.7% ·
DBVT
DBV Technologies SA - American
Jul 17, 2026 BUY Buy
+70.4% avg upside
15 analysts
$45.00
219.43% Upside
-2.9% ·
AVBP
ArriVent BioPharma, Inc.
Jul 14, 2026 BUY Strong Buy
+35.6% avg upside
15 analysts
$42.00
33.86% Upside
-6.2% ·
ABVX
Abivax SA Sponsored ADR
Jun 30, 2026 BUY Strong Buy
+6.0% avg upside
15 analysts
$170.00
34.02% Upside
-5.8% ·
PYXS
Pyxis Oncology
May 23, 2026 BUY Strong Buy
+159.7% avg upside
14 analysts
$6.00
112.03% Upside
+128.8% ·
IMUX
Immunic
May 16, 2026 BUY Strong Buy
+158.7% avg upside
21 analysts
$56.00
261.67% Upside
+22.6% ·
GYRE
Gyre Therapeutics
Aug 09, 2023 HOLD Strong Buy
+210.5% avg upside
15 analysts
+103.9% ·
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Sam Slutsky — Frequently Asked Questions
How accurate are Sam Slutsky's stock ratings?
Based on the calls 13Foresight could measure, about 53% of Sam's ratings were profitable over a one-year hold, with an average return of +9.3% per rating, or +7.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sam ranked on 13Foresight?
Sam Slutsky is currently ranked #638 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sam cover?
Sam most recently has ratings on OLMA, DMRA, SYRE, ORKA, COGT, ELVN, IMVT, CGON, CLDX, IFRX, ALXO, OKUR and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.